Browse News
Filter News
Found 53 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
1/23/2024
BeiGene, Ltd., a global biotechnology company, announced that Olivier Brandicourt, M.D. has been appointed to its Board of Directors.
-
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS
1/16/2024
Dewpoint Therapeutics Inc. announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concept study of c-mods in a chronic C9orf72 repeat, the most common genetic cause of ALS.
-
Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS
1/7/2024
Dewpoint Therapeutics Inc. announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis.
-
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
11/7/2023
Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programs of condensate modifying therapeutics to Investigational New Drug Applications using Evotec’s industry-leading fully integrated data-driven platform.
-
Dewpoint Therapeutics Partners with Chemify to Apply Groundbreaking Chemistry AI to Radically Accelerate the Discovery of Molecules Targeting Cancer and Neurodegeneration
9/12/2023
Dewpoint Therapeutics and Chemify today announced a partnership to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify's programmable chemistry platform against condensate targets of interest in Dewpoint's oncology and neurodegeneration pipeline.
-
PureTech Announces Annual Results for Year Ended December 31, 2022
4/28/2023
Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million 1 and consolidated cash, cash equivalents and short-term investments of $350.1 million, 2 as of December 31, 2022.
-
Novo Nordisk and Dewpoint Therapeutics have inked a deal to use the latter's biomolecular condensates discovery platform to treat insulin resistance and diabetic complications.
-
Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression
3/22/2023
Dewpoint Therapeutics today announced a research and development partnership with Novo Nordisk to identify drug candidates using Dewpoint's discovery platform related to biomolecular condensates to treat insulin resistance and diabetic complications.
-
Dewpoint Therapeutics Granted Second Breakthrough Condensates Platform Technology Patent by US Patent Office
11/14/2022
Dewpoint Therapeutics Inc. announced the U.S. Patent and Trademark Office issued the patent "Methods of Characterizing Condensate-Associated Characteristics of Compounds and Uses Thereof" covering novel technology for partitioning and identifying compounds which preferentially partition into condensates of interest.
-
Human Immunology Biosciences Launches to Lead Clinical Immunology into Its Next Chapter with $120 Million Financing
11/1/2022
Human Immunology Biosciences, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases, announced its launch with $120 million in financing.
-
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
10/25/2022
Actinium Pharmaceuticals, Inc. today highlighted multiple additions to its senior leadership team including Jenny Hsieh as Chief Strategy Officer, Sunitha Lakshminarayanan, as Senior Vice President, Head of CMC and Product Development, and Stephen Dressel as Vice President, Strategic Finance and Analysis.
-
Breakthrough Prize in Life Sciences awarded to Anthony Hyman, Ph.D., pioneer of biomolecular condensates and co-founder of Dewpoint Therapeutics
9/22/2022
Dewpoint Therapeutics, Inc. today announced biomolecular scientist Anthony (Tony) Hyman was awarded the 2023 Breakthrough Prize in Life Sciences for discovering a new mechanism of cellular organization mediated by phase separation of proteins and RNA into membraneless liquid droplets called condensates.
-
Oppenheimer Hires Joel Sendek As Head of Healthcare Life Sciences Research Team, Further Bolstering the Firm's Commitment to an Important Area of Focus
9/15/2022
Oppenheimer & Co. Inc. announced the ongoing expansion of its Healthcare Life Sciences Research Team within the firm's Equity Research Department with the appointment of Joel Sendek as Managing Director and Head of Healthcare Life Sciences Equity Research.
-
How Might Biomolecular Condensates Revolutionize Drug Discovery? A Perspective from Dewpoint Therapeutics
8/17/2022
A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery.
-
Anthony Hyman, Ph.D., pioneer of biomolecular condensates and co-founder of Dewpoint Therapeutics, recognized with two leading science awards
7/21/2022
Dewpoint Therapeutics, Inc. announced biomolecular scientist Anthony Hyman, head of the Max Planck Institute of Molecular Cell Biology and Genetics, and a co-founder of Dewpoint Therapeutics, has been honored with two of the world's top scientific awards for his pioneering work investigating the role of biomolecular condensates in the origin of disease.
-
Dewpoint Therapeutics Granted Foundational Platform Technology Patent by US Patent Office
5/25/2022
Dewpoint Therapeutics Inc. , today announced the US Patent and Trademark Office (USPTO) issued the patent "Methods of Screening for Condensate-Associated Specificity and Uses Thereof" (U.S. Patent No. 11,340,231) covering novel technology for screening compounds capable of modulating biomolecular condensates with high selectivity.
-
Bristol Myers Squibb Company forged an oncology drug discovery and development deal valued at more than $1 billion with Volastra Therapeutics.
-
Dewpoint Therapeutics Appoints Aravind Subramanian, Ph.D., as Head of Digital & Technology Platforms
2/28/2022
Dewpoint Therapeutics today announced the appointment of Aravind Subramanian , Ph.D., as Head of Digital & Technology Platforms.
-
The funds raised will advance several of Dewpoint's programs to IND status with the FDA and enhance its multi-component biology platform and AI-driven data science platform.